In this position paper FEAM acknowledges the importance of the significant advances that have taken place over the last few years in the science and application of genome editing, aided by the development of new techniques such as CRISPR/Cas9. FEAM also recognises that the rapid development of this technology and its potential to deliberately introduce modifications to the human germline, has also been responsible for driving forwards the current ethical and regulatory debate over the possibility of its future application in the clinic.
To read more click here
